Figure 6.

Western blot and real-time RT-PCR analysis of LC3B and SQSTM1 with in vivo retinas. (A and B) Western blot analyses of LC3B (A) and SQSTM1 (B) with in vivo retinas. (Ai) Representative western blot analyses of LC3B. (Aii and Aiii) Quantitative western blot analysis of LC3B-I (Aii) and LC3B-II expression (Aiii) (n = 4 per experiment, Tukey *p < 0.05). (Bi) Representative western blot analyses of SQSTM1. (Bii) Quantitative western blot analysis of SQSTM1 expression (n = 4 per experiment, Tukey *p < 0.05). (Ci) Representative western blot analyses of LC3B. (Cii and Ciii) Quantitative western blot analysis of LC3B-I (Cii) and LC3B-II expression (Ciii) (n = 4 per experiment, Tukey *p < 0.05). Treatment with rapamycin or torin 2 significantly increased in the expression of LC3B-II in OH eyes compared with AlloP-treated OH eyes. Co-administration of AlloP with bafilomycin A₁ induced a remarkable increase in LC3B-II expression compared with AlloP administration in OH eyes. (Di) Representative western blot analyses of SQSTM1. (Dii) Quantitative western blot analysis of SQSTM1 (n = 4 per experiment, Tukey *p < 0.05). Treatment with rapamycin or torin 2 decreased SQSTM1 expression in OH eyes compared with AlloP-treated OH eyes. Co-administration of AlloP with bafilomycin A₁ significantly increased SQSTM1 expression compared with AlloP-treated OH eyes. (E) Real-time RT-PCR analysis of Lc3b (Ei) and Sqstm1 mRNA (Eii) (n = 10 per experiment, Tukey *p < 0.05). (Ei) Lc3b mRNA was significantly increased in OH eyes treated with AlloP compared with non-treated OH eyes. Co-administration of AlloP with bafilomycin A₁ induced no remarkable difference in Lc3b mRNA expression compared with AlloP-treated OH eyes. (Eii) AlloP induced no remarkable changes in Sqstm1 mRNA expression in OH eyes compared with non-treated OH eyes. Administration of AlloP or co-administration of AlloP with bafilomycin A₁ induced no remarkable difference in Sqstm1 mRNA expression in OH eyes